3 months ago
LLY
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Sectors:
Industries:
Analyst Ranking
Bottom 11%
#4360 out of 4868 analysts
Average Return
-4.28%
Win Rate
34%21 out of 62
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Verastem IncVSTM | +200.80% | $2.49 | $7.49 | 2024-08-12 - 2025-04-30 | Strong Buy |
Verastem IncVSTM | +186.97% | $2.61 | $7.49 | 2024-07-07 - 2025-04-30 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-27 - 2024-06-27 | Strong Buy |
Scholar Rock Holding CorpSRRK | +113.66% | $15.23 | $32.54 | 2024-04-02 - 2025-04-02 | Strong Buy |
Scholar Rock Holding CorpSRRK | +111.18% | $16.01 | $33.81 | 2024-03-24 - 2025-03-24 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
4 months ago
PFE
5 months ago
EWTX
5 months ago
SRRK
7 months ago
LLY
10 months ago
LLY
a year ago
LLY
a year ago
KYMR
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals IncREGN | 7 | Strong Buy | $940.00 | +56.99% | Maintains | 15 hours ago |
Biogen IncBIIB | 4 | Strong Buy | $199.00 | +64.35% | Maintains | 2 days ago |
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | +73.13% | Maintains | 22 days ago |
Incyte CorpINCY | 9 | Hold | $72.00 | +14.91% | Maintains | a month ago |
Protagonist Therapeutics IncPTGX | 2 | Strong Buy | $76.00 | +65.87% | Maintains | 2 months ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $1,038.00 | +15.47% | Maintains | 3 months ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | +11.23% | Maintains | 3 months ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | +31.09% | Maintains | 4 months ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | +204.88% | Maintains | 5 months ago |
Scholar Rock Holding CorpSRRK | 4 | Strong Buy | $45.00 | +36.74% | Maintains | 5 months ago |
Kymera Therapeutics IncKYMR | 3 | Strong Buy | $53.00 | +54.65% | Reiterates | 6 months ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | +2,471.43% | Upgrades | 7 months ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | +100.27% | Maintains | 9 months ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | +212.23% | Initiates Coverage On | 9 months ago |
Cytokinetics IncCYTK | 4 | Strong Buy | $70.00 | +63.40% | Maintains | a year ago |
Affimed NvAFMD | 2 | Strong Buy | $60.00 | N/A | Maintains | 2 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 2 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.